期刊文献+

CD7在非淋巴造血组织中的表达 被引量:1

The expression of CD7 in nonhematopoietic tissues
下载PDF
导出
摘要 目的探索CD7在非淋巴造血组织的表达情况,并总结其规律。方法收集北京友谊医院病理科多种不同组织切片283例,观察HE切片组织形态,应用免疫组织化学EliVision法对多组织芯片进行CD7筛查,然后与雌激素受体(ER)进行同切片的对比分析。结果 CD7在乳腺组织中51.15%(67/131)、子宫内膜组织中100%(18/18)、宫颈组织中100%(15/15)、输卵管组织中100%(2/2)、卵巢组织中44.4%(4/9)、前列腺组织中33.3%(1/3)出现细胞核阳性表达;其余数种组织均未出现CD7细胞核表达。CD7在非淋巴造血组织中的表达定位在细胞核,而不在细胞膜。ER在乳腺组织中53.44%(70/131)、子宫内膜组织中100%(18/18)、宫颈组织中100%(15/15)、输卵管组织中100%(2/2)、卵巢组织中33.3%(3/9)、前列腺组织中33.3%(1/3)出现细胞核阳性表达;其余数种组织均未出现ER表达。结论①CD7不仅可以在淋巴造血组织中表达,也可在一些非淋巴造血组织中表达;②CD7仅在非淋巴造血组织的细胞核中表达;③CD7与ER表达的组织类型基本吻合。 Objective To explore the expression of CD7 in nonhematopoietic tissues, then summarize its regular patterns. Methods Two hundred eighty - three different tissue samples obtained from Beijing Friendship Hospital were examined by Elivision immunohistochemical staining for CD7 and estrogen receptor (ER). Results CD7 expression was four/d in mammary gland tissue (67 of 131,51.15% ), endometrial tissue ( 18 of 18, 100% ), cervix tissue ( 15 of 15, 100% ), oviduct tissue (2 of 2, 100% ), ovary tissue (4 of 9, 44.4% ) and prostate gland tissue ( 1 of 3,33.3% ). Other tissues were CD7 negative. In addition, it is observed that CD7 expression in nonhematopoietic tissues was located in the nucleus but not the membrane of the cells. ER expression was found in mammary gland tissue (70 of 131,53.44% ), endometrial tissue ( 18 of 18, 100% ), cervix tissue ( 15 of 15, 100% ), oviduct tissues (2 of 2, 100% ), ovary tissue (3 of 9, 33.3% ) and prostate gland tissue ( 1 of 3, 33.3% ). No ER expression was observed in other tissues. Conclusion ①CD7 expression is not only observed in the hematopoietic tis- sues, but also in the nonhematopoietic tissues. ②CD7 expression in the nonhematopoietic tissues is limited in the nucleus. ③Thc tissue types are basically the same for the expressions of CD7 and ER.
作者 岳冰 周小鸽
出处 《临床和实验医学杂志》 2014年第2期81-84,共4页 Journal of Clinical and Experimental Medicine
关键词 非淋巴造血组织 CD7 雌激素受体 Nonhematopoietic tissue CD7 Estrogen receptor
  • 相关文献

参考文献10

  • 1Went P,Agostinelli C,Gallamini A. Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score[J].{H}Journal of Clinical Oncology,2006,(16):2472-2479.
  • 2Liu V,McKee PH. Cutaneous T-cell lymphoproliferative disorders:approach for the surgical pathologist:recent advances and clarification of confused issues[J].{H}ADVANCES IN ANATOMIC PATHOLOGY,2002,(02):79-100.
  • 3Rogers SL,Zhao Y,Jiang X. Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia[J].{H}Molecular Cancer Therapautics,2010,(09):41.
  • 4Aandahl EM,Quigley MF,Moretto WJ. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection:correlation with antigenic load and reversion by antiretroviral treatment[J].{H}Blood,2004,(12):3672-3678.
  • 5Chu PG,Arber DA,Weiss LM. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms.An immunohistochemical study of 447 cases[J].{H}American Journal of Clinical Pathology,2003,(01):64-70.
  • 6周小鸽.全国性免疫组织化学质量控制活动介绍及总结[J].临床与实验病理学杂志,2007,23(4):510-511. 被引量:10
  • 7刘晓霞,翟曜耀,赵越.雌激素受体ERα的功能调控及相关疾病的研究进展[J].中国细胞生物学学报,2011,33(1):65-71. 被引量:22
  • 8赵晓民,徐小明.雌激素受体及其作用机制[J].西北农林科技大学学报(自然科学版),2004,32(12):154-158. 被引量:29
  • 9Fiets WE,Bellot FE,Struikmans H. Prognosis value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumors[J].{H}EUROPEAN JOURNAL OF SURGICAL ONCOLOGY,2005,(02):128-133.
  • 10王跃华,赵铁,周娜.雌激素受体、孕激素受体、p53基因和C-erbB-2在乳腺癌组织中的表达及意义[J].中国临床保健杂志,2006,9(4):360-361. 被引量:13

二级参考文献61

  • 1程广源.乳腺癌标志物的临床意义[J].癌症进展,2004,2(5):400-405. 被引量:7
  • 2于志勇,于金明,吴泰璜,卓培英,王圣芳,李美,张霞,吕宝玉,刘雁冰.乳腺癌分子生物学特性检测的临床意义[J].中华肿瘤杂志,2005,27(7):420-422. 被引量:14
  • 3熊慧华,于世英,夏曙,庄亮.Expression of Survivin, Mutant p53 and C-erbB-2 in Breast Cancer and Its Clinical Significance[J].The Chinese-German Journal of Clinical Oncology,2005,4(4):229-231. 被引量:7
  • 4Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S, et al. A TFTC/STAGA module medistes histone H2A and H2B deubiquitination, coactivates nuclear receptor and counteracts hererochromatin silencing. Mol Cell 2008; 29(1): 92-101.
  • 5Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC, et al. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Mol Cell Biol 2007; 27(14): 5090-104.
  • 6Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A, Poirier MC, et al. Tamoxifen induces expression of immune responserelated genes in cultured normal human mammary epithelial cells. Cancer Res 2009; 69(3): 1150-55.
  • 7Higgins KJ, Liu S, Abdelrahim M, Vanderlaag K, Liu X, Porter W, et al. Vascular endothelial growth factor receptor-2 expression is down-regulated by 17β-estradiol in MCF-7 breast cancer cells by estrogen receptor α/Sp proteins. Mol Endocrinol 2008; 22(2): 388-402.
  • 8Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14(2): 121-41.
  • 9Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103(6): 843-52.
  • 10Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor α transcriptional activity. Mol Cell Biol 2007; 27(17): 5933-48.

共引文献70

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部